

SWIXX BIOPHARMA RECOGNIZED IN THE 2024 FT1000 LIST - ONE OF EUROPE'S FASTEST- GROWING COMPANIES

March 4th, 2024

Baar, Switzerland – Swixx BioPharma AG of Baar, Switzerland, is delighted to announce that it has been recognized as one of Europe's Fastest-Growing Companies for 2024 by the *Financial Times (FT)*. The latest FT / Statista ranking of Europe's fastest-growing companies has included Swixx Biopharma in the prestigious FT1000 list. Swixx BioPharma was ranked 9 of all European companies in the Health Care & Life Sciences sector, with a 70,6% Compound Annual Growth Rate (CAGR).

Swixx's CEO, Jean-Michel Lespinasse, enthused that being featured "in the FT1000 list marks a significant, objective recognition of the extraordinary growth Swixx has enjoyed in the last years. This acknowledgment reaffirms our vision to become the No. 1 Commercial platform not only in CEE, but beyond – into other markets where our partners consider that Swixx can be of service.... My sincere congratulations go to each member of our Swixx team. I thank them for their dedication, passion, and commitment to excellence, which have provided the driving force to power our growth."

Dezso Marta, Swixx's Chief Operational Officer CEE, elaborated that "we are very excited to be recognized in the FT 1000. The listing recognizes not only a stunning financial metric (extraordinary sales growth), but implicitly showcases Swixx's ability to deliver unmatched market access for new product launches. In a word, our superb teams are adept at delivering exceptional service for our partners across all geographies. The results speak for themselves. Inclusion in the FT1000 list will be a powerful motivator for everyone at Swixx and a great source of pride."

About FT1000 - Europe's Fastest-Growing Companies 2024

The FT1000 list is an annual ranking compiled by the *Financial Times* in collaboration with Statista. It recognizes and celebrates the fastest-growing companies with headquarters in Europe that act largely independently in their business decisions and do not derive financial benefits from their parent company, based on their revenue growth over a specified period, typically three years. The FT1000 list for 2024 covers the years 2019 to 2022. The minimum growth rate included was 36.3%. Full report is available on the link <https://www.ft.com/ft1000-2024>.

About Swixx BioPharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, Russia, and several Eurasian countries including Belarus, Kazakhstan and Uzbekistan. With over 1,300 employees and sales which exceeded 900M Euros in 2023, Swixx has swiftly evolved into one of the largest and fastest-growing dedicated agents for biopharma in the Central, Eastern and Southeastern regions of Europe. The company opened in MENA in late 2023 and now has a regional HQ in Dubai. Swixx has gathered outstanding rare disease, oncology-hematology, specialty, vaccines, and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com.

Contact: Vedrana Sokac Brataljenovic, Public Affairs Director, Swixx BioPharma AG
vedrana.sokac@swixxbiopharma.com
Tel: +385 1 425 6086

